Key Points
- CEO Miranda Jayne Toledano acquired 11,000 shares of ENTX at $1.81 on Dec. 29 for $19,910, increasing her stake to 426,575 shares (a 2.65% ownership increase).
- Entera Bio (NASDAQ:ENTX) trades around $2.00 with a market cap of about $91.7M and a 52‑week range of $1.50–$3.22; the company reported -$0.07 EPS last quarter (beats) but still has negative ROE and very large net loss margins.
- Institutional investors own roughly 14.11% of the stock, and analysts are mixed — MarketBeat's consensus is a "Moderate Buy" with an average target of $10.00, though some firms rate the stock a sell.
Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) CEO Miranda Jayne Toledano acquired 11,000 shares of the stock in a transaction on Monday, December 29th. The shares were bought at an average price of $1.81 per share, for a total transaction of $19,910.00. Following the purchase, the chief executive officer owned 426,575 shares in the company, valued at approximately $772,100.75. This trade represents a 2.65% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.
Entera Bio Stock Performance
NASDAQ:ENTX opened at $2.00 on Wednesday. The company has a market cap of $91.71 million, a price-to-earnings ratio of -8.00 and a beta of 1.71. Entera Bio Ltd. has a fifty-two week low of $1.50 and a fifty-two week high of $3.22. The stock has a fifty day moving average price of $2.37 and a 200-day moving average price of $2.12.
Entera Bio (NASDAQ:ENTX - Get Free Report) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.02. Entera Bio had a negative return on equity of 67.56% and a negative net margin of 4,525.11%. Research analysts predict that Entera Bio Ltd. will post -0.28 EPS for the current fiscal year.
Hedge Funds Weigh In On Entera Bio
A number of institutional investors have recently added to or reduced their stakes in ENTX. HighTower Advisors LLC lifted its stake in Entera Bio by 53.3% in the 1st quarter. HighTower Advisors LLC now owns 18,140 shares of the company's stock valued at $31,000 after purchasing an additional 6,310 shares during the last quarter. Citadel Advisors LLC lifted its stake in shares of Entera Bio by 243.0% in the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company's stock valued at $77,000 after acquiring an additional 28,322 shares during the last quarter. Bessemer Group Inc. acquired a new stake in shares of Entera Bio during the 2nd quarter valued at $268,000. Finally, Parkman Healthcare Partners LLC grew its position in Entera Bio by 6.3% during the 1st quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company's stock worth $747,000 after acquiring an additional 25,900 shares during the last quarter. 14.11% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several analysts recently issued reports on ENTX shares. Wall Street Zen upgraded shares of Entera Bio to a "sell" rating in a research report on Saturday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Entera Bio in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Entera Bio presently has a consensus rating of "Moderate Buy" and an average target price of $10.00.
View Our Latest Research Report on ENTX
About Entera Bio
(
Get Free Report)
Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.
The company's lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
